Misoprostol-only Regimen

Answers for healthcare providers on routes of misoprostol administration and what they mean for medication abortion care.

LNG-IUD and the risk of gynecologic and breast cancers, contraception and body weight, and preferred ways to get hormonal birth control.

Doctor-messengers are valuable communicators about abortion, impact of the shot on medication abortion efficacy, common misconceptions about IUDs, and precoital EC.

Young people’s concerns about birth control and fertility, expanding EPT and PrEP in the ED, spike in EC demand around the New Year, and abortion decision making.

Highlighting one notable research article from each Research Roundup in 2023.

COX-2 inhibitor demonstrates potential in increasing efficacy of OTC LNG-EC pills; updated systematic review and meta-analysis supporting the effectiveness and safety of misoprostol-alone for medication abortion; support needs of adolescents and young adult abortion seekers; and more!

Continued support for misoprostol-only regimens for medication abortion and self-managed abortion between nine and 16 weeks gestation, the use of home pregnancy tests for follow-up care after a telehealth medication abortion, where adolescents and young adults go online to get abortion information, and disparities in recommended retesting for women with trichomonas vaginalis infections.

Perceived pain and sedation dosing during abortion procedures by demographics, PAPP-A as a novel screening for gestational age before medication abortion, patient experiences with progestin-only pills and attitudes towards OTC access.